- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Latest Oncology News
Second-Line Lisocabtagene Maraleucel Provides Benefit in Large B-Cell Lymphoma
August 10, 2022
Findings from the phase 2 PILOT study reveal lisocabtagene maraleucel to provide benefit as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation.
CAR T Cells Have Potential as Earlier-Line Therapy for Multiple Myeloma
August 10, 2022
Jesus G. Berdeja, MD, discusses the potential of chimeric antigen receptor T-cell therapy to be approved for earlier lines of treatment in multiple myeloma.
Ide-cel Prolongs Progression-Free Survival in Heavily Pretreated R/R Multiple Myeloma
August 10, 2022
Results from the interim analysis of phase 3 KarMMa-3 study indicate improvement in progression-free survival with idecabtagene vicleucel compared with standard combination regimens, as well as better responses.
KEYNOTE-921 Trial of Pembrolizumab and Chemo Fails to Improve Survival in mCRPC
August 10, 2022
The phase 3 KEYNOTE-921 trial did not meet its coprimary end points of overall survival and radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer.
As Backlog of Delayed Cancer Screenings are Addressed, Inequities in Care Persist
August 10, 2022
In an interview with Targeted OncologyTM, Debra Patt, MD, PhD, MBA, FASCO, discusses the impact of delayed cancer screenings in potential patients and how the COVID-19 pandemic has increased existing inequities in cancer care.
Nivolumab and Ipilimumab Shows Promising Responses in Advanced Classical Kaposi Sarcoma
August 09, 2022
Results from a phase 2 study revealed nivolumab plus ipilimumab to demonstrate promising clinical activity and manageable safety signals in previously treated patients with classical Kaposi sarcoma who had disease progression.
Upfront Avelumab Shows Modest Survival Benefit Over Chemo in Advanced PD-L1+ NSCLC
August 09, 2022
Survival outcomes of avelumab in patients with PD-L1-positive non-small cell lung cancer showed numeric improvement compared with chemotherapy, but missed the significance threshold in the JAVELIN Lung 100 study.
Tislelizumab Displays Overall Survival Benefit in Unresectable HCC
August 09, 2022
The phase 3 RATIONALE 301 trial of tislelizumab in patients with unresectable hepatocellular carcinoma has met its primary end point of non-inferior overall survival.
Implementing Screening Can Double Survival for Patients With Lung Cancer
August 09, 2022
An easy way to double survival for patients with lung cancer is by removing the barriers to screening.
Findings of the IMMUTACE Trial in Hepatocellular Carcinoma
August 09, 2022
Arndt Vogel, MD, discusses the study results of the IMMUTACE study in hepatocellular carcinoma.
Fruquintinib Plus BSC Significantly Improves Overall Survival in Metastatic CRC
August 09, 2022
The combination of fruquintinib and best supportive care improved overall survival vs BSC alone in patients with metastatic colorectal cancer.
Adjuvant Pembrolizumab Improves Secondary Efficacy End Points in RCC
August 09, 2022
Toni K. Choueiri, MD, discusses results from the KEYNOTE-564 efficacy analysis of adjuvant pembrolizumab in renal cell carcinoma.